Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
CNY 18.41
(-1.13%)
CNY 18.41
(-1.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 58.28 Million | 146.56 Million | -67.74 Million | 42.81 Million | 112.76 Million | 105.57 Million |
| Net Income | -6.18 Million | 45.12 Million | 96.54 Million | 135.7 Million | 126.01 Million | 87.77 Million |
| Depreciation & Amortization | 47.02 Million | 43.49 Million | 26.99 Million | 12.16 Million | 11.89 Million | 11 Million |
| Deferred income taxes | -16.07 Million | 7.69 Million | -17.55 Million | 669.96 Thousand | -179.24 Thousand | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 34.28 Million | 51.69 Million | -204.68 Million | -117.4 Million | -34.68 Million | -2.96 Million |
| Other non-cash items | 11.8 Million | 6.25 Million | 13.4 Million | 12.34 Million | 9.54 Million | 9.75 Million |
| Investing Cash Flow | 9.31 Million | -443.81 Million | -192.34 Million | -172.27 Million | -120.97 Million | -172.72 Million |
| Investments in PPE | -139.28 Million | -248.44 Million | -171.09 Million | -152.33 Million | -114.97 Million | -172.72 Million |
| Acquisitions | 3.02 Million | -9.79 Million | -18.57 Million | 29.15 Thousand | - | 450.00 |
| Investment purchases | -242.77 Million | -25 Million | -2.9 Million | -19.96 Million | - | - |
| Sales/Maturities of investments | 2.2 Million | 19.84 Million | 0.40 | -29.15 Thousand | - | - |
| Other Investing Activities | 389.14 Million | -180.42 Million | 230.64 Thousand | 29.15 Thousand | -6 Million | 450.00 |
| Financing Cash Flow | 97.57 Million | 178.74 Million | -53.96 Million | 568.89 Million | 87.22 Million | 40.24 Million |
| Debt repayment | -117.03 Million | -51 Million | -14.7 Million | -181.17 Million | -28.5 Million | -28.5 Million |
| Dividends payments | -7.01 Million | -43.43 Million | -80.43 Million | -7.83 Million | -5.72 Million | -1.42 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -11.99 Million | 275.48 Million | 41.72 Million | 757.9 Million | 121.44 Million | 70.16 Million |
| Accounts receivables | 67.53 Million | 38.15 Million | -151.67 Million | -122.42 Million | -53.36 Million | - |
| Accounts payables | 20.43 Million | 8.97 Million | 10.15 Million | 26.2 Million | 6.04 Million | - |
| Inventory | -37.6 Million | -3.12 Million | -45.61 Million | -21.84 Million | 12.8 Million | 1.31 Million |
| Other working capital | 4.35 Million | 7.69 Million | -17.55 Million | 669.95 Thousand | -179.24 Thousand | -4.27 Million |
| Cash at beginning of period | 161.4 Million | 279.91 Million | 593.97 Million | 154.54 Million | 75.53 Million | 102.44 Million |
| Cash at end of period | 326.58 Million | 161.4 Million | 279.91 Million | 593.97 Million | 154.54 Million | 75.53 Million |
| Capital Expenditure | -139.28 Million | -248.44 Million | -171.09 Million | -152.33 Million | -114.97 Million | -172.72 Million |
| Effect of forex changes on cash | - | 0.93 | - | - | 0.85 | - |
| Net cash flow / Change in cash | 165.17 Million | -118.51 Million | -314.05 Million | 439.43 Million | 79 Million | -26.91 Million |
| Free Cash Flow | -80.99 Million | -101.87 Million | -238.84 Million | -109.52 Million | -2.21 Million | -67.15 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | -10.14 Million | 24.33 Million | -77.38 Million | -6.18 Million | 4.72 Million |
| Depreciation & Amortization | - | 14.76 Million | 14.76 Million | 47.02 Million | 47.02 Million | -24.1 Million |
| Deferred income taxes | - | - | - | - | -16.07 Million | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -43.55 Million | - | 29.93 Million | 34.28 Million | 6.42 Million |
| Other non-cash items | - | 28.21 Million | -40.77 Million | 31.73 Million | 11.8 Million | -7.98 Million |
| Investing Cash Flow | 20.72 Million | 30.55 Million | 153.56 Million | 121.64 Million | 9.31 Million | -272.67 Million |
| Investments in PPE | -34.21 Million | -25.17 Million | -37.4 Million | -16.28 Million | -139.28 Million | -31.67 Million |
| Acquisitions | - | -1.85 Million | - | 3.01 Million | 3.02 Million | - |
| Investment purchases | - | 60 Million | -60 Million | -242.77 Million | -242.77 Million | - |
| Sales/Maturities of investments | - | 231 Million | 10 Million | 250.02 Million | 2.2 Million | - |
| Other Investing Activities | 54.94 Million | -233.4 Million | 241 Million | 380.69 Million | 389.14 Million | -241 Million |
| Financing Cash Flow | -1.01 Million | 62.66 Million | -241.13 Million | -21.12 Million | 97.57 Million | 49.27 Million |
| Debt repayment | -159.86 Thousand | -159.25 Million | -239.83 Million | -2.68 Million | -117.03 Million | -180 Million |
| Dividends payments | -856.69 Thousand | -39.39 Million | -1.29 Million | -2.99 Million | -7.01 Million | -1.71 Million |
| Common Stock Repurchased | - | -49.99 Million | - | -3 Million | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -39.39 Million | -1.29 Million | -14.99 Million | -11.99 Million | 230.99 Million |
| Accounts receivables | - | -62.53 Million | - | 67.53 Million | 67.53 Million | -14.56 Million |
| Accounts payables | - | - | - | - | 20.43 Million | - |
| Inventory | - | 18.97 Million | - | -37.6 Million | -37.6 Million | 20.98 Million |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 319.1 Million | 226.17 Million | 329.92 Million | 194.75 Million | 161.4 Million | 439.09 Million |
| Cash at end of period | 323.47 Million | 320.58 Million | 225.92 Million | 326.58 Million | 326.58 Million | 194.75 Million |
| Capital Expenditure | -34.21 Million | -25.17 Million | -37.4 Million | -16.28 Million | -139.28 Million | -31.67 Million |
| Effect of forex changes on cash | - | - | - | - | - | -0.29 |
| Net cash flow / Change in cash | 4.36 Million | 94.4 Million | -104 Million | 131.82 Million | 165.17 Million | -244.34 Million |
| Free Cash Flow | -34.21 Million | -21.86 Million | -53.84 Million | 15.01 Million | -80.99 Million | -52.62 Million |
QRIL
300596
MANGIND
KSCL
002197
2901